Apolipoprotein A-I Mimetic Peptides: Discordance Between In Vitro and In Vivo Properties-Brief Report

Arteriosclerosis, Thrombosis, and Vascular Biology
Michael DitiatkovskiDmitri Sviridov

Abstract

Apolipoprotein A-I (apoA-I) mimetic peptides have antiatherogenic properties of high-density lipoprotein in vitro and have been shown to inhibit atherosclerosis in vivo. It is unclear, however, if each in vitro antiatherogenic property of these peptides translates to a corresponding activity in vivo, and if so, which of these contributes most to reduce atherosclerosis. The effect of 7 apoA-I mimetic peptides, which were developed to selectively reproduce a specific component of the antiatherogenic properties of apoA-I, on the development of atherosclerosis was investigated in apolipoprotein E-deficient mice fed a high-fat diet for 4 or 12 weeks. The peptides include those that selectively upregulate cholesterol efflux, or are anti-inflammatory, or have antioxidation properties. All the peptides studied effectively inhibited the in vivo development of atherosclerosis in this model to the same extent. However, none of the peptides had the same selective effect in vivo as they had exhibited in vitro. None of the tested peptides affected plasma lipoprotein profile; capacity of plasma to support cholesterol efflux was increased modestly and similarly for all peptides. There is a discordance between the selective in vitro and in vivo...Continue Reading

References

Jan 1, 1994·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·Y NakashimaR Ross
Apr 4, 2008·Journal of Atherosclerosis and Thrombosis·Dmitri SviridovPaul Nestel
Dec 8, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Fatiha TabetGilles Lambert
May 21, 2010·The Journal of Pharmacology and Experimental Therapeutics·Marcelo J A AmarAlan T Remaley
Sep 30, 2010·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Geoffrey D WoolGodfrey S Getz
Nov 29, 2015·The Biochemical Journal·Dmitri Sviridov, Alan T Remaley

❮ Previous
Next ❯

Citations

Oct 26, 2018·Arteriosclerosis, Thrombosis, and Vascular Biology·Jacqueline S DronRobert A Hegele
Dec 27, 2018·Arteriosclerosis, Thrombosis, and Vascular Biology·Yunosuke MatsuuraKarin E Bornfeldt
Nov 30, 2019·The Journal of Pharmacology and Experimental Therapeutics·Maria V FawazAnna Schwendeman
Jan 26, 2020·International Journal of Molecular Sciences·Jiansheng HuangHui Huang
Mar 25, 2020·Journal of Lipid Research·Dmitri SviridovYury I Miller
Mar 28, 2019·Arteriosclerosis, Thrombosis, and Vascular Biology·Congqing WuHong S Lu
Aug 24, 2017·Drug Development Research·David Gurwitz
Oct 26, 2018·Arteriosclerosis, Thrombosis, and Vascular Biology·Hong S LuAlan Daugherty
Nov 2, 2019·Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids·Andrea Rivas-UrbinaJose Luis Sánchez-Quesada
Dec 9, 2020·Metabolism: Clinical and Experimental·Eftaxia-Konstantina ValantiDespina Sanoudou
Mar 16, 2021·Journal of Lipid Research·Dmitri SviridovYury I Miller
Jul 16, 2021·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Hongliang HeAnna Schwendeman

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.